MX2018003403A - Anticuerpos biespecificos anti-cd3 optimizados y sus usos. - Google Patents

Anticuerpos biespecificos anti-cd3 optimizados y sus usos.

Info

Publication number
MX2018003403A
MX2018003403A MX2018003403A MX2018003403A MX2018003403A MX 2018003403 A MX2018003403 A MX 2018003403A MX 2018003403 A MX2018003403 A MX 2018003403A MX 2018003403 A MX2018003403 A MX 2018003403A MX 2018003403 A MX2018003403 A MX 2018003403A
Authority
MX
Mexico
Prior art keywords
antigen
antibodies
binding
certain embodiments
present
Prior art date
Application number
MX2018003403A
Other languages
English (en)
Inventor
Chen Gang
Smith Eric
Macdonald Douglas
Babb Robert
Haber Lauric
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018003403A publication Critical patent/MX2018003403A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos que se fijan a CD3 con afinidad de fijación débil o no detectable y métodos para usarlos. De acuerdo con algunas formas de realización, los anticuerpos de la invención se fijan en CD3 humano con afinidad baja e inducen la proliferación de linfocitos T humanos y, por lo tanto, inducen la inactivación mediada por linfocitos T de células tumorales con eficacia alta. De acuerdo con algunas formas de realización, la presente invención proporciona moléculas de fijación al antígeno biespecíficas que comprenden un primer demonio de fijación al antígeno que se fija específicamente a CD3 humano con afinidad de fijación débil o no detectable en un ensayo in vitro, y una segunda molécula de fijación al antígeno que se fina específicamente al antígeno asociado al tumor humano. En algunas formas de realización, las moléculas de fijación al antígeno biespecíficas de la presente invención son capaces de inhibir el crecimiento de tumores que expresan el antígeno diana, tales como PSMA. Los anticuerpos y las moléculas de fijación al antígeno biespecíficas de la invención son útiles para el tratamiento de enfermedades y trastornos en donde una respuesta inmunitaria regulada de manera ascendente o inducida es deseable y/o terapéuticamente beneficiosa. Por ejemplo, los anticuerpos de la invención son útiles para el tratamiento de varios tipos de cáncer u otras enfermedades en donde la inmunoterapia, es decir, la inmunomodulación de células efectoras, está garantizada.
MX2018003403A 2015-09-23 2016-09-23 Anticuerpos biespecificos anti-cd3 optimizados y sus usos. MX2018003403A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222605P 2015-09-23 2015-09-23
PCT/US2016/053525 WO2017053856A1 (en) 2015-09-23 2016-09-23 Optimized anti-cd3 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018003403A true MX2018003403A (es) 2018-05-28

Family

ID=57130447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003403A MX2018003403A (es) 2015-09-23 2016-09-23 Anticuerpos biespecificos anti-cd3 optimizados y sus usos.

Country Status (28)

Country Link
US (2) US20180355038A1 (es)
EP (1) EP3353212B1 (es)
JP (3) JP7023231B2 (es)
KR (1) KR20180050412A (es)
CN (1) CN108290951B (es)
AU (1) AU2016325630B2 (es)
BR (1) BR112018005445A2 (es)
CA (1) CA2999385A1 (es)
CY (1) CY1124944T1 (es)
DK (1) DK3353212T3 (es)
EA (1) EA201890785A1 (es)
ES (1) ES2901133T3 (es)
HK (1) HK1258304A1 (es)
HR (1) HRP20220133T8 (es)
HU (1) HUE057683T2 (es)
IL (1) IL258036B (es)
LT (1) LT3353212T (es)
MA (1) MA42935B1 (es)
MD (1) MD3353212T2 (es)
MX (1) MX2018003403A (es)
MY (1) MY195059A (es)
PL (1) PL3353212T3 (es)
PT (1) PT3353212T (es)
RS (1) RS62859B1 (es)
SI (1) SI3353212T1 (es)
TW (2) TWI784917B (es)
WO (1) WO2017053856A1 (es)
ZA (1) ZA201801673B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
HUE050831T2 (hu) 2014-11-17 2021-01-28 Regeneron Pharma Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
AU2016242866B2 (en) 2015-03-30 2021-06-03 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to FC gamma receptors
CA2987403A1 (en) * 2015-05-28 2016-12-01 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
BR112018071285A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores, vetor, sistema, e, método
SG10202010155YA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of expression-enhancing loci
WO2018067331A1 (en) * 2016-09-23 2018-04-12 Regeneron Pharmaceuticals, Inc. Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CN111201242A (zh) * 2017-06-22 2020-05-26 财团法人生物技术开发中心 不对称异二聚fc-scfv融合抗globo h及抗cd3双特异性抗体及其在癌症治疗上的用途
EA201990784A1 (ru) * 2017-09-14 2019-09-30 Ридженерон Фармасьютикалз, Инк. Анти-muc16 (mucin16) антитела
MX2020002976A (es) * 2017-09-29 2020-07-24 Regeneron Pharma Moleculas de union a antigeno biespecificas que se unen a un antigeno objetivo de staphylococcus y a un componente de complemento, y usos de las mismas.
WO2019133761A1 (en) * 2017-12-27 2019-07-04 Teneobio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
TW202005985A (zh) * 2018-06-21 2020-02-01 美商再生元醫藥公司 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
BR112020025926A2 (pt) 2018-06-21 2021-03-23 Regeneron Pharmaceuticals, Inc. anticorpos biespecíficos anti-psma x anti-cd28 e usos dos mesmos
WO2020010079A2 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
SG11202100252SA (en) * 2018-07-19 2021-02-25 Regeneron Pharma BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
AU2019331024A1 (en) 2018-08-31 2021-03-18 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CN113518647A (zh) 2018-10-11 2021-10-19 印希比股份有限公司 5t4单域抗体及其治疗性组合物
AU2019356573A1 (en) 2018-10-11 2021-05-27 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
TW202028246A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 B7h3單域抗體及其治療性組合物
JP2022511813A (ja) * 2018-12-04 2022-02-01 ノバルティス アーゲー Ｃｄ３に対する結合分子及びその使用
TWI821474B (zh) * 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
BR112021010238A2 (pt) 2018-12-19 2021-08-24 Regeneron Pharmaceuticals, Inc. Anticorpos anti-cd28 x anti-cd22 biespecíficos e usos dos mesmos
MX2021006971A (es) 2018-12-19 2021-07-15 Regeneron Pharma Anticuerpos anti-muc16 x anti-cd28 biespecificos y usos de estos.
EP3941941A1 (en) 2019-03-22 2022-01-26 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
MA56515A (fr) * 2019-06-21 2022-04-27 Regeneron Pharma Utilisation de molécules de liaison à l'antigène bispécifiques se liant à psma et cd3 en combinaison avec une co-stimulation de 4-1bb
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
CN114302893A (zh) 2019-08-15 2022-04-08 瑞泽恩制药公司 用于细胞靶向的多特异性抗原结合分子及其用途
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
CN114929343A (zh) 2019-12-06 2022-08-19 瑞泽恩制药公司 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023097219A2 (en) * 2021-11-24 2023-06-01 Adimab, Llc Anti-idiotype antibodies
TW202346337A (zh) 2022-03-29 2023-12-01 美商恩格姆生物製藥公司 Ilt3及cd3結合劑以及其使用方法
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN114685675B (zh) * 2022-04-27 2023-02-03 深圳市汉科生物工程有限公司 双特异性抗体及其在治疗癌症中的用途
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024081180A1 (en) 2022-10-10 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for reducing alloantibody levels in subjects in need of solid organ transplantation
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2461631A1 (en) * 2001-09-28 2003-04-03 Elusys Therapeutics, Inc. Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
ATE455127T1 (de) 2003-05-31 2010-01-15 Micromet Ag Humane anti-humane cd3-bindungsmoleküle
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CN104072614B (zh) * 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
AU2009313389A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
ME02352B (me) * 2010-08-12 2016-06-20 Lilly Co Eli PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA
WO2013026839A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2013157105A1 (ja) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN104582476B (zh) * 2012-06-05 2017-03-08 瑞泽恩制药公司 使用共同轻链制备完全人双特异性抗体的方法
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
DK2900694T3 (en) * 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
RU2015117393A (ru) * 2012-10-08 2016-12-10 Роше Гликарт Аг Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN112062853B (zh) * 2013-12-20 2024-01-09 豪夫迈·罗氏有限公司 双特异性her2抗体及使用方法
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها

Also Published As

Publication number Publication date
AU2016325630A1 (en) 2018-04-26
MA42935A (fr) 2018-08-01
EP3353212B1 (en) 2021-11-03
MA42935B1 (fr) 2022-02-28
EA201890785A1 (ru) 2018-10-31
HRP20220133T8 (hr) 2022-05-13
CN108290951B (zh) 2022-04-01
TW201726713A (zh) 2017-08-01
WO2017053856A1 (en) 2017-03-30
MY195059A (en) 2023-01-05
ZA201801673B (en) 2022-12-21
MD3353212T2 (ro) 2022-03-31
JP2018537516A (ja) 2018-12-20
AU2016325630B2 (en) 2022-11-17
CA2999385A1 (en) 2017-03-30
EP3353212A1 (en) 2018-08-01
TWI784917B (zh) 2022-11-21
KR20180050412A (ko) 2018-05-14
LT3353212T (lt) 2021-12-27
CY1124944T1 (el) 2023-01-05
RS62859B1 (sr) 2022-02-28
TWI783914B (zh) 2022-11-21
PL3353212T3 (pl) 2022-03-28
US20180355038A1 (en) 2018-12-13
HUE057683T2 (hu) 2022-05-28
JP2022064886A (ja) 2022-04-26
JP2023154021A (ja) 2023-10-18
IL258036B (en) 2022-09-01
HK1258304A1 (zh) 2019-11-08
HRP20220133T1 (hr) 2022-04-15
TW202241514A (zh) 2022-11-01
US20210253701A1 (en) 2021-08-19
ES2901133T3 (es) 2022-03-21
BR112018005445A2 (pt) 2018-10-09
DK3353212T3 (da) 2021-12-20
CN108290951A (zh) 2018-07-17
SI3353212T1 (sl) 2022-01-31
JP7023231B2 (ja) 2022-02-21
IL258036A (en) 2018-05-31
PT3353212T (pt) 2022-01-05

Similar Documents

Publication Publication Date Title
MY195059A (en) Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
PH12020552116A1 (en) Bispecific anti-psma x anti-cd28 antibodies and uses thereof
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
MX2020004410A (es) Anticuerpos biespecificos con funciones efectoras reducidas.
PH12021551238A1 (en) Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof
PH12021550031A1 (en) BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
EA201491686A1 (ru) Мультиспецифические антигенсвязывающие молекулы и их применения
MX2021015271A (es) Uso de moleculas biespecificas de union a antigeno que se unen a psma y cd3 en combinacion con la estimulacion conjunta de 4-1bb.
EA202190089A1 (ru) Биспецифичные антитела анти-psma x анти-cd28 и их применения
EA201991227A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения
EA202090303A3 (ru) Композиции антител для лечения опухолей